The FARAPULSE™ Pulsed Field Ablation System is now FDA approved! FARAPULSE™ offers tissue selective cardiac #ablation for the treatment of PAF which minimizes thermal risk. See the FARAPULSE™ difference: https://t.co/ch1o7AcENY
Safety info: https://t.co/gRtvxWHcGw
The AVANT GUARD clinical trial has commenced and will evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF). Learn more: https://t.co/Uz9AK9cym3
The WATCHMAN FLX™ Pro LAAC Device featuring HEMOCOAT™ Technology takes the next step forward in #LAAC with three first-ever features to advance performance and safety and optimize healing. Learn more ➡ https://t.co/QbXdiBYOkT
IFU: https://t.co/SXy3XCXTzv
A two year journey, with the FROZEN-AF IDE clinical trial in July 2020 to post approval launch this week. We successfully completed multiple procedures using this system using zero fluoroscopy as we completed the first cases in Arkansas to launch the system since FDA approval. What a journey this has been coming the full circle from the IDE trial to the commercial launch . So proud of our team at Arrhythmia Research Group @StBernards and White River Medical center for living this journey with me . #epeeps @BSCCardiology@WomenAs1 #ArrhythmiaResearchGroup
Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo)Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo)Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo)Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo)Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo)Just in from #ESCCongress! FARAPULSE™ Pulsed Field Ablation System has met all end points for primary safety and efficacy in the ADVENT Pivotal Trial and been shown to be non-inferior to standard-of-care thermal ablation (RF and Cryo).
Join us for the EU-PORIA Late-Breaking Clinical Trial on May 20 and learn more about real world use of FARAPULSE™ only at #HRS2023. https://t.co/l0sXyDAIAh
Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Discover how the ADVENT Pivotal Trial will bridge the crucial gap in understanding the impact of FARAPULSE™.
https://t.co/KnWJJ3OWIc
Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Congratulations to @VivekReddyMD and team on the first procedure of the ADVANTAGE AF trial using the FARAPULSE™ PFA System.
Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.
View real world clinical & pre-clinical publications and explore the data behind the FARAPULSE™ PFA System here: https://t.co/BlDfs7bhT8
Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.
In the IMPULSE, PEFCAT and PEFCAT II trials, FARAPULSE™ PFA System use reported a durable isolation of 96% of PVs. See the data here: https://t.co/4PtNriSWVU
Caution: Investigational Device. Limited by US law to investigational use only. Not available for sale.
Join us for the next Virtual #MedEd Program & peer-to-peer discussion led by @DavidBDeLurgio, @PaulMahoneyMD & @sean_pokorney on the most recent and largest real-world data release by the ACC NCDR #LAAO Registry. Reserve your spot for the June 15 program: https://t.co/9z4MlF74VH
SURPASS is the largest WATCHMAN FLX study to date with 16,048 patients. The 0.37% safety endpoint confirmed the best-in-class safety profile of WATCHMAN FLX in real-world use. https://t.co/lMd1hhBGWW #CRT2022#CardioTwitter
Evolved from 20 years of WATCHMAN innovation and experience gained from 150,000+ successful implants, WATCHMAN FLX is the #LAAC technology with proven safety and trusted patient outcomes. See the data: https://t.co/4fQQhwfZya
Check out the on-demand session focused on the head-to-head comparison data on device closure, #LAAC clinical data, evidence gaps, and more at #TCT2021. Info: https://t.co/9fmgAziggm
See the newly published 12-month data from the PINNACLE FLX trial, now available via @CircAHA: https://t.co/pGiKQIng8f
Safety info: https://t.co/hCEsphE5Cs
Over 150,000 people have left blood thinners behind with WATCHMAN #LAAC, the one-time, minimally invasive procedure that protects your #NVAF patients for life. Learn more at https://t.co/Xohuawzkpg
With nearly 700 WATCHMAN Implants, Dr. Doug Gibson discusses his experience deploying the new WATCHMAN FLX™ #LAAC Device.
Safety info: https://t.co/dSgaxqlCpT